🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 10/11/1997 | 15,00 | 15,13 | 14,75 | 14,81 | +0,64% | 2,50% | 196.600 |
| 07/11/1997 | 14,75 | 15,50 | 14,50 | 14,72 | -2,28% | 6,78% | 319.800 |
| 06/11/1997 | 15,19 | 15,31 | 14,81 | 15,06 | -0,82% | 3,29% | 307.600 |
| 05/11/1997 | 15,19 | 15,56 | 15,00 | 15,19 | +1,67% | 3,70% | 275.600 |
| 04/11/1997 | 15,00 | 15,63 | 14,81 | 14,94 | -0,42% | 5,42% | 307.600 |
| 03/11/1997 | 14,81 | 15,25 | 14,50 | 15,00 | +1,69% | 5,06% | 409.200 |
| 31/10/1997 | 15,19 | 15,25 | 14,50 | 14,75 | -1,26% | 4,94% | 554.800 |
| 30/10/1997 | 14,75 | 15,31 | 14,63 | 14,94 | -2,45% | 4,66% | 192.200 |
| 29/10/1997 | 15,38 | 15,63 | 15,13 | 15,31 | +2,51% | 3,25% | 460.400 |
| 28/10/1997 | 14,63 | 15,81 | 14,13 | 14,94 | -2,45% | 11,54% | 1.055.600 |
| 27/10/1997 | 16,25 | 16,50 | 15,19 | 15,31 | -8,58% | 8,08% | 289.800 |
| 24/10/1997 | 16,94 | 17,19 | 16,38 | 16,75 | +0,00% | 4,80% | 169.000 |
| 23/10/1997 | 16,63 | 17,19 | 16,19 | 16,75 | -0,74% | 6,02% | 198.600 |
| 22/10/1997 | 16,81 | 17,19 | 16,63 | 16,88 | +1,50% | 3,35% | 271.200 |
| 21/10/1997 | 16,44 | 16,88 | 16,19 | 16,63 | +2,31% | 4,18% | 406.600 |
| 20/10/1997 | 16,13 | 16,38 | 15,75 | 16,25 | +0,39% | 3,88% | 644.000 |
| 17/10/1997 | 16,81 | 17,06 | 15,44 | 16,19 | -4,43% | 9,67% | 722.200 |
| 16/10/1997 | 17,56 | 17,56 | 16,75 | 16,94 | -3,21% | 4,63% | 364.200 |
| 15/10/1997 | 17,56 | 17,63 | 17,19 | 17,50 | +0,36% | 2,49% | 202.400 |
| 14/10/1997 | 17,50 | 17,63 | 17,00 | 17,44 | +1,45% | 3,57% | 703.600 |
| 13/10/1997 | 18,75 | 18,75 | 17,19 | 17,19 | -5,50% | 8,33% | 977.000 |
| 10/10/1997 | 17,44 | 18,38 | 17,44 | 18,19 | +2,46% | 5,38% | 796.000 |
| 09/10/1997 | 16,63 | 17,94 | 16,56 | 17,75 | +6,77% | 8,27% | 865.600 |
| 08/10/1997 | 16,88 | 16,88 | 16,44 | 16,63 | -0,37% | 2,59% | 961.800 |
| 07/10/1997 | 17,19 | 17,25 | 16,56 | 16,69 | -2,55% | 4,00% | 867.400 |
| 06/10/1997 | 17,56 | 17,56 | 17,00 | 17,13 | -1,79% | 3,20% | 266.000 |
| 03/10/1997 | 17,44 | 18,44 | 17,19 | 17,44 | +2,57% | 7,17% | 914.200 |
| 02/10/1997 | 17,88 | 17,88 | 16,75 | 17,00 | -4,23% | 6,29% | 1.655.400 |
| 01/10/1997 | 18,88 | 19,19 | 17,69 | 17,75 | -5,96% | 7,95% | 1.170.200 |
| 30/09/1997 | 20,00 | 20,13 | 18,88 | 18,88 | -2,89% | 6,25% | 915.200 |